Inhibitor Therapeutics (INTI) Short Interest Ratio & Short Volume

Short interest is the volume of Inhibitor Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 2,300 shares of INTI short. Learn More on Inhibitor Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INTI shares currently have a short interest ratio of 2.0. Learn More on Inhibitor Therapeutics's short interest ratio.

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Inhibitor Therapeutics: GlycoMimetics, Inc. (9.45%), KALA BIO, Inc. (0.36%), BioVie Inc. (3.18%), Alaunos Therapeutics, Inc. (9.57%), MEI Pharma, Inc. (0.37%), Sol-Gel Technologies Ltd. (0.04%), Galecto, Inc. (0.42%), Flora Growth Corp. (1.40%), Benitec Biopharma Inc. (6.27%), NeuroBo Pharmaceuticals, Inc. (2.06%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

Short selling INTI is an investing strategy that aims to generate trading profit from Inhibitor Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Inhibitor Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of INTI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INTI, twice per month. The most recent reporting period available is April, 30 2024.